Adobe Stock
Abbott India will report its January-March 2025 (Q4 FY25) results on 15 May , and all eyes are on whether the pharma major can extend its consistent streak of double-digit profit growth. The company has benefited from a potent mix of price hikes, product innovation, and disciplined cost control—elements that continue to support its steady climb.
Performance Snapshot Over Four Quarters
| Quarter | Revenue (₹ crore) | YoY Change | Net Profit (₹ crore) | YoY Change | Key Drivers |
|---|---|---|---|---|---|
| Q3 FY25 | 1614 | +12 per cent | 361 | +16 per cent | Demand for Digene, Thyronorm and cardiac therapies offset higher raw-material costs. |
| Q2 FY25 | 1633 | +9 per cent | 359 | +15 per cent | Volume gains and selective price hikes cushioned margin pressures. |
| Q1 FY25 | 1558 | +5 per cent | 328 | +13 per cent | Price-uncapped portfolio drove topline despite a soft cough/cold season. |
| Q4 FY24 | 1439 | +7 per cent | 287 | +24 per cent | Tight expense control aided sharp earnings jump; ₹410/sh dividend declared. |
What to Watch This Quarter
-
Sustained Pricing Power:
Abbott's flagship drugs mostly fall outside India's price control list, allowing the company to regularly implement 2-4 per cent price hikes . Gross margins are expected to remain robust at 61-62 per cent . -
Margin Outlook:
Analysts expect EBITDA margins of 23-24 per cent , supported by higher operating leverage despite inflation in API costs. -
New Product Momentum:
Recent launches in gastro-intestinal, women's health, and metabolic care are scaling faster than peers. Uptake in these areas could set the tone for FY26 growth. -
Peer Comparison:
While companies like Cipla and GSK Pharma have posted healthy profit growth, Abbott's strength in chronic therapies has ensured better margin consistency.
Value Research Stock Rating Check-Up
Metric
Score
Quality
10/10
Growth
7/10
Valuation
3/10
Momentum
8/10
Abbott India continues to justify its quality premium , thanks to a debt-free balance sheet , strong return on capital , and a resilient brand portfolio . However, its valuation remains steep, trading at ~ 48x trailing earnings , significantly above sector averages.
Bottom Line
Expect another solid quarter of mid-teens profit growth backed by pricing strength and disciplined operations. Unless cost inflation surprises or management guides for changes in pricing strategy, Abbott's story of steady compounding is likely to continue.
For long-term investors , the stock's high quality may still justify its premium. New entrants , however, might find better opportunities after potential post-results volatility .
For detailed financial information, visit our stock page- Abbott India
Disclaimer: This article has been written with the assistance of Artificial Intelligence. While our digital writer has been trained to follow our editorial style, we recommend applying a critical eye while reading. Enjoy the story — and keep smiling with understanding!
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
